Compare ARI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | IMCR |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2009 | 2016 |
| Metric | ARI | IMCR |
|---|---|---|
| Price | $10.92 | $30.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $11.00 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 1.3M | 366.2K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.31% | N/A |
| EPS Growth | ★ 183.51 | 30.39 |
| EPS | 0.16 | ★ 0.25 |
| Revenue | ★ $271,589,000.00 | $249,428,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | N/A | $8.21 |
| P/E Ratio | ★ $68.09 | $122.22 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $9.39 | $27.47 |
| 52 Week High | $11.24 | $40.71 |
| Indicator | ARI | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 50.13 |
| Support Level | $9.59 | $28.90 |
| Resistance Level | $11.17 | $34.35 |
| Average True Range (ATR) | 0.14 | 1.32 |
| MACD | -0.03 | 0.18 |
| Stochastic Oscillator | 55.26 | 61.98 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.